Introduction
Health technology assessment (HTA) increasingly plays an important role in informing reimbursement and pricing decisions and providing clinical guidance on the use of medical technologies across the world. In addition to safety and efficacy information, health economic and outcomes research data are also receiving expanded attention in these assessments in many countries, due to payers seeking better value for money spent on treatments. HTA is now commonly viewed as a tool to assist evidence-based health-care decisions. It has had various definitions over the years and across countries, but as defined herein, it is the systematic evaluation of a medical or health technology for evidence of its safety, efficacy, effectiveness, cost, cost-effectiveness, and ethical and legal implications, both in absolute terms and in comparison with other competing technologies.
Several groups have developed or recommended good practices for the conduct of HTA. [2] [3] [4] [5] However, little is known about actual adherence to such recommended principles within HTA organizations. This paper attempts to address this gap by retrofitting the results of an international survey of HTA organizations and reimbursement bodies regarding HTA research practices, methodologies, and key issues to 15 HTA principles proposed in a recent publication for assessing HTA activities that involve allocation of resources (Table 1) . 2 Specifically, the objectives of this paper are to (1) describe research methods used internationally in health technology assessment (HTA) and health-care reimbursement policies, (2) compare the survey findings on research methods and processes to published HTA principles, and (3) discuss important issues/trends reported by HTA bodies related to current research methods and applications of the HTA process.
Methods
An online survey was developed consisting of 47 items within four topics related to (1) organizational information and process, (2) primary HTA methodologies and importance of attributes, (3) HTA application and dissemination, Seventy-one HTA and/or reimbursement bodies from 27 countries were targeted for inclusion in the survey. Respondents from targeted countries were recruited from internal HTA contact lists residing at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), as well as contacts available through working group members in various countries. Respondents were not paid and provided their contact information at the conclusion of the survey if additional follow-up was needed. Efforts were made to target key individuals within the organizations who would be knowledgeable and senior enough to provide insight to the survey questions. Working group members were assigned individual contacts to follow-up via electronic mail and telephone calls.
The survey data were analyzed and presented in this paper as a retrofit with the 15 HTA principles (Table 1) proposed by Drummond et al, 2 with the addition of key trends and issues in HTA methodology, application, and process. Our survey was developed in tandem with the principles, thus we retrofitted our data to fit the various categories as applicable, as our survey was designed to be broader than the principles and focus on research methods. The survey items are listed in the appendix to this paper.
Key findings
The survey was completed by 30 respondents from a mix of regions/countries: Australia (n = 3; 10%), Canada (n = 2; 6%), Europe (n = 17; 57%), Latin America (n = 2; 6%), and the United States (n = 6; 20%) ( Table 2 ). The types of agencies/ organizations responding were categorized as HTA only (58%), reimbursement only (7%), both HTA and reimbursement (17%), and other (17%; eg, third-party payers and pharmacy benefit managers [PBMs]). In spite of the variety of and number of payers, respondents from the US were limited and reflected primarily a government payer or independent Principle 2. The HTA should be an unbiased and transparent exercise
The optimal HTA process is conducted independently of the group that will decide on payment or reimbursement, while the HTA process and basis on which decisions are made should be transparent. In our survey, only 17% of respondents indicated a combined HTA and reimbursement role. The majority of funding for HTA came from the government for most respondents (63%); however, the HTA work itself was likely to be partially outsourced. Among the survey respondents, HTA work was performed by either in-house staff (30%), academia (37%), or a combination of in-house HTA staff and outsourcing to independent professional consultants (63%). Among our respondents, 27% always involved stakeholders (primarily manufacturers of the health technologies) in the health technology assessment, 27% sometimes involved stakeholders, and 57% gave stakeholders a chance to review a draft version of the assessment before the report was finalized. Methods and results of the assessments were made available to the public by 80% of respondents. A majority (90%) of the respondents made these reports freely available, while 7% charged a fee for the reports. The survey did not specifically ask whether complete versus partial results were made available to the public. , and technologies with declining use in practice were rarely assessed by respondents (less than 14% across all technologies). Selection of the comparator(s) was driven by the authoritative bodies for about 50% of the respondents, while both client requests and reasonable comparators selected by the group conducting the HTA were other common approaches. In addition to placebo, the most used or prescribed other health technologies were selected as comparators for more than 50% of respondents.
Principle 4. A clear system for setting priorities for HTA should exist
Understanding how technologies are selected and prioritized for assessment is crucial to determining the potential bias associated with situations where only select technologies are evaluated. Our survey indicated that more than half of all respondents reported potential cost and perceived impact on patient outcomes were the main criteria for selecting health technologies (regardless of whether drug, device, or other technology). Prevalence of a medical condition was also an important factor in selection for an assessment, with approximately half of the respondents requiring an evaluation of the burden of disease in the population specific to the market in submit your manuscript | www.dovepress.com
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Stephens et al which the technology was being assessed (∼53% for drug, 63% for medical devices, and 47% for other technologies This principle seeks to emphasize the role of guidelines and systematic approaches to evidence synthesis and analysis during an HTA review. More complex statistical and methodological techniques are used to address gaps in the available data for a technology (eg, lack of a head-to-head study with a key comparator). We found the starting point and primary methodology used for synthesis of evidence was either systematic review or meta-analysis (.50% across technologies). In addition, we found that meta-analyses (38% of respondents) and comparative analyses (34%) were the most common methodologies being used for drug therapies. For medical devices, post-marketing surveillance (38%) was also a common method, along with meta-analyses (45%) and comparative analyses (36%). Table 3 provides a summary of the most common methods used by region for drugs and medical devices. Figure 1 summarizes the overall frequency of various methods employed for HTA of drugs and medical devices. For bodies that consider cost or costeffectiveness information, the most common analyses were cost-effectiveness (.75% for drugs and medical devices), with the primary methodology being decision models ($70% for drugs and medical devices, and 57% for other technologies). Common end points included cost/life-year saved, cost/event avoided, and cost/quality-adjusted life year (QALY). However, cost-effectiveness information was only evaluated for conformance with economic evaluation or pharmacoeconomic guidelines by 47% of respondents for drugs and 33% for medical devices. For the most part, European agencies had clearly defined national guidelines they followed, while US agencies were less organized, with only one (of six total) respondent stating the Academy of Managed Care Pharmacy format as a guideline was followed. stakeholder views are included in the review process. Although randomized clinical trials are needed to establish efficacy and achieve regulatory approval, our survey indicates that the most common attributes assessed in HTA processes are effectiveness, safety, costs, and cost-effectiveness across technologies and evolutionary stages. Figure 2 presents the relative importance of the attributes assessed, and shows the attributes are not weighted equally. While cost and costeffectiveness are commonly assessed as part of HTA review, effectiveness was rated as the most important attribute, with approximately 80% of respondents rating it highly important for both drugs and medical devices, followed by safety (.70% for drugs and medical devices, .50% for other technologies). Differences by region were also noted among 0% S y s t e m a t i c r e v i e w C o s t / e c o n a n a l y s e s M e t a -a n a l y s e s C o m p a r a t i v e a n a l y s e s M o d e l i n g C l i n i c a l t r i a l s E p i / o b s e r v a t i o n a l a n a l y s e s E x p e r t o p i n i o n P o s t -m a r k e t i n g s u r v e i l l a n c e G r o u p j u d g m e n t S y s t e m a t i c r e v i e w C o s t / e c o n a n a l y s e s M e t a -a n a l y s e s C o m p a r a t i v e a n a l y s e s M o d e l i n g C l i n i c a l t r i a l s E p i / o b s e r v a t i o n a l a n a l y s e s E x p e r t o p i n i o n P o s t -m a r k e t i n g s u r v e i l l a n c e 
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Stephens et al There is some concern that selection of narrowly defined perspectives for HTA may distort clinical decision-making and policy regarding new technologies. Our survey indicated that at least half of the respondents used a societal perspective regardless of technology, followed by ∼35% using primarily a third-party payer perspective. Differences by region were significant. Europe uses a societal perspective (67% across technologies), while the US is more oriented to third-party payers and other perspectives (22% and 33%, respectively). While the societal perspective was most commonly reported, the use of cost per QALY end points was generally not mandatory.
Principle 8. HTAs should explicitly characterize uncertainty surrounding estimates
The use of sensitivity analyses are considered essential to understanding the robustness of HTA findings and c onclusions. Quantification of the uncertainty surrounding the estimates may be achieved through one-way, multiway, and probabilistic sensitivity analyses. Our survey specifically focused the question on characterizing uncertainty around cost-effectiveness estimates. Only about half of our survey respondents that included cost-effectiveness as one of the assessed HTA components required mandatory estimation of uncertainty (using confidence intervals) around the costeffectiveness estimates for both drug and medical device evaluations. Countries reporting mandatory estimates of uncertainty included Denmark, France, Germany, Hungary, the Netherlands, Portugal, and Sweden.
Principle 9. HTAs should consider and address issues of generalizability and transferability
Given the international nature of our survey, the issues of generalizability and transferability of HTA findings, and specifically cost-effectiveness data, were of particular focus. All respondents considered foreign HTA evaluations in their own process in some way. European agencies were more specific about the organizations they considered, while US HTA agencies were open to any with good methodologies. More than half of the respondents required an understanding of the burden/epidemiology specific to the market in which the technology was being assessed. Furthermore, international data (eg, from multinational trials) may be accepted in some countries, while country-specific or regional/province data is required by other countries. In general, international patient utilities and QoL data are accepted (about 50% across technologies). However, resource-utilization data was split between international data being permitted versus requiring country-specific data (about 30% each, across technologies). Not surprisingly, data on unit costs or price weights was more often required to be country-specific (about 50% for drugs and medical devices). To understand all key stakeholders at various stages of the HTA process, it is important to recognize that HTA is primarily initiated by government bodies (80%); however, in the US, it is initiated by government and HTA agencies with equal frequency. With regard to funding, HTAs are also almost entirely government funded, followed by mostly government with some private contributions (∼30%). However, in the US, HTAs are frequently privately funded. The issue of funding seems to play out in the stakeholder involvement. For example, our survey indicated that stakeholders are often (57%) given a chance to review a draft version of the assessment before the report is finalized, a process most frequent in the US (67%). However, approximately half of respondents do not involve stakeholders in the assessment itself. With regard to the final decisions, more than half of the respondents (57%) reported that stakeholders are never involved; in these cases, there is an appeals process in place if stakeholders do not agree with the final decision.
Principle 11. Those undertaking HTAs should actively seek all available data
This principle supports the use of proprietary/confidential data from industry sponsors, as well as use of publicly available data. While this specific question was not directly posed in our survey, we do know that certain agencies accept confidential information as part of the submission, and often these analyses reflect patient-level data analysis as part of the modeling exercises. We are also aware that the CMS will accept confidential data; however, they cannot use it in decision-making unless it is made publicly available. [6] [7] Given the responses to our stakeholder questions in the survey, we found that it was more frequent than not that the industry sponsor was in some way involved in the assessment, indicating a certain level of collaboration.
Principle 12. The implementation of HTA findings needs to be monitored
The outcome of HTA decisions may indicate whether the HTA exercise is in fact useful. Eighty-six percent of respondents indicated that the organization making the decision on coverage or reimbursement at least partially relied on the conclusions of the assessment. However, only 28% repeat or update the assessment at regular intervals, indicating that prospective tracking of the outcome of the decisions being made generally do not happen on a widespread basis.
Use in decision-making Principle 
HTA should be timely
Timing of the HTA is important; however, long-term and effectiveness data are generally not available when a new technology is approved. Conditional reimbursement was not directly addressed in the survey, as to whether thorough assessment is delayed until adequate data are available. However, timely reassessment appears to be more popular in the US, where at least half of respondents reported performing annual reassessments, while the majority of European respondents do not require mandatory reassessment at any specific regular interval.
Principle 14. HTA findings need to be communicated appropriately to different decision-makers
This principle suggests that the HTA results should be tailored to various users of the information. Our survey indicated that the backgrounds of users of HTA information do indeed vary and include physicians/specialists and health economists as the most common technical backgrounds (73% and 57%, respectively). Interestingly, pharmacists were more common users of the assessments among our respondents in the US than Europe (83% vs 41%). The most common modes of communication for HTA findings were the agency's or government's website (83%), followed by peer-reviewed journals (57%). Our survey respondents that represented European reimbursement agencies indicated that HTA reports they had received were considered excellent in all but one case, while US responses indicated that the quality of reports was either "poor" or "fair" approximately half of the time.
Principle 15. The link between HTA findings and decision-making processes needs to be transparent and clearly defined This principle describes the separation of the assessment itself from the actual decision-making to avoid equity issues. One such issue is the use of a specific threshold of cost-effectiveness above which the technology would not be funded. Though the use of an explicit threshold appears to the most transparent approach, it may not account for other variables (eg, lack of alternative treatments in advanced cancers where CE thresholds often exceed the generally acceptable limits, or lack of robust data in appropriate population with appropriate comparator). Our survey indicated this was indeed the case, with at least 60% of respondents indicating that specific thresholds were not used to determine whether a technology was cost-effective. To support transparency in decisionmaking, 90% of survey respondents indicated that the HTA report itself was free and that the methods and results of the assessments were made available to the public almost 90% of the time in Europe and about two-thirds of the time in the US. The survey also suggests that the conclusion of the submit your manuscript | www.dovepress.com
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Stephens et al assessment is only partially relied upon by the organizations making decisions (.80% of respondents indicated partial reliance on HTA conclusions; 7% of respondents indicated complete reliance).
Key issues and trends for HTA bodies
In conducting the survey, one goal was to understand better the issues and trends facing HTA with regard to research methods. We asked respondents in an open-ended format what the key issues, trends, or topics their agencies or organizations were facing with regard to methodologies used for HTA. A summary of key themes is shown by country in Table 5 . The key concerns appear to be linked to the stage of evolution of HTA in the various countries. Common themes included meta-analysis methods for indirect comparisons. Lack of data upon which to base the assessments was also a key challenge. The US entities described a lack of good data from solid, peer-reviewed literature to use as inputs in metaanalyses and analytic framework modeling. European agencies frequently mentioned standardization of methodology and a lack of evidence for emerging technologies. Countries with well-established HTA programs indicated that timeliness and reassessment strategy was of key concern.
Features of the process, application and use of HTA Beyond research methods, the survey also included questions related to the process and application of HTA. Given the heterogeneity among regions surveyed, we synthesized results for the European respondents (56% of survey respondents and 69% of countries represented), as they generally had more mature HTA processes and systems in place. Figure 3 provides an overview of the characteristics of HTA from the European respondents, technical backgrounds of those making decisions based on the HTA report, use of the findings, methods of dissemination, and stakeholder involvement. Of interest is that the conduct of the HTA is most frequently outsourced or provided by academia in Europe, while the reader of the HTA report and decision-maker is most frequently a physician/specialist.
Discussion
Our survey represents the first published data focusing specifically on HTA research methods gathered directly from representatives within these bodies. It is also the first attempt using prospective survey data to compare conformity of research methods with the 15 HTA principles published by Drummond et al in 2008. 2 Previously published studies focused on either Europe or the US, 1, [8] [9] [10] [11] [12] and more recent HTA surveys have focused on structural characteristics, regional drivers of decision-making, and transferability of HTA to other regions rather than on specific research methods employed. [13] [14] [15] Neumann and colleagues (from the 15 HTA principles group) used a literature-review approach to assess conformity with these HTA principles. 10 While their review provides some insight into conformity with the principles, it was limited by the availability of published data, some of which was more than 10 years old. Results presented in this paper reflect a recent snapshot of HTA research methods and processes.
While none of the countries responding appeared to be meeting all of the recommended HTA principles, the survey results indicate that there are different approaches and priorities between the various countries surveyed and even within countries when different payers are involved. The finding that in most cases the HTA reports are only partially relied upon in decision-making raises interesting questions about what this indicates related to usefulness of the HTA and the consequences. Perhaps it simply reflects unwillingness by decision-makers to give too much power to HTA agencies, given that the coverage decisions can be politically charged and other aspects have to be considered such as situations with orphan drugs, rare diseases, or children. The primary limitation with this international survey was the response rate of 25% (30 out of 121 contacts within 71 organizations). Even with direct contact by email and phone calls, we achieved limited or no response from some countries or payers within countries. For instance, representatives of the National Institute for Clinical Excellence did not directly respond to the survey, but rather referred us to their website, and hence this established organization was not represented in our survey results. In addition, some respondents did not complete the entire survey.
In the US, there was significant resistance to providing the type of detail requested about research methods and priorities within the assessments. Nevertheless, there was a diverse representation to reflect the different perspectives within the US, including three independent HTA bodies, a government payer (CMS), a large MCO, and a PBM. Findings within the US were particularly surprising, and suggested that QoL assessment was more frequently assessed and considered of submit your manuscript | www.dovepress.com
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Stephens et al higher importance than in Europe (where cost-effectiveness seemed more important). Even MCO and PBM respondents ranked QoL as of medium importance, when it has been generally perceived in the US that MCOs do not value QoL end points in their decision-making. However, a recent survey of 46 US managed care decision-makers appeared to confirm our findings. 11 Payers reported that the QoL supplemental information provided in the Academy of Managed Care Pharmacy dossiers is considered one of the more useful sections: 62% reported that the patient reported outcomes/QoL section was useful, compared to 81% for systematic reviews/ meta-analyses, 62% for pharmacoeconomic studies, 42% retrospective/observational safety/adverse events studies, 42% persistence/adherence studies, 38% prospective observational cohort studies, 19% patient registries, 19% patient-preference studies, 15% indirect comparisons of clinical benefit, and 12% predictive-risk models.
Another limitation was the presentation of the international survey data as a retrofit to the HTA principles. Not all questions were designed to address each principle, as we were developing our survey as the principles were being released, and so we gathered additional information on the specific research methods used in HTA beyond what was specified in the principles. Future research could be conducted to specifically assess conformity with each of the HTA principles from the outset. In addition, expansion of the respondent base in key emerging markets, such as the Asia-Pacific region, would be valuable and of interest for future reports.
In conclusion, the use of research methods and conformity to published HTA principles varied significantly by country and payer. Despite our relatively small sample, the results suggest that HTA, using evidence-based medicine, will continue to be a rapidly evolving area and in need of standardized research methods and principles to guide assessment and decision-making around drug therapies, medical devices, and emerging technologies. A process for information sharing among HTA bodies may be needed to achieve this standardization in research methods. Future research would be useful to update and expand the results of this survey to address specifically additional aspects of the HTA principles and changes in research methods applied. 
